Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement ClaritySeeking Alpha • Friday
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is SayingSeeking Alpha • Wednesday
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer TranscriptSeeking Alpha • 10/23/26
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response RateMarketBeat • 10/23/26
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer DrugInvestors Business Daily • 10/23/26
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development StrategyGlobeNewsWire • 10/23/26
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026GlobeNewsWire • 10/16/26
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?Zacks Investment Research • 09/10/26
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/03/26
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/01/26
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher ExpensesZacks Investment Research • 08/12/26
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%Zacks Investment Research • 07/22/26
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer TranscriptSeeking Alpha • 06/08/26